Dynamic partnerships for maximum impact: How our collaboration with Tandem Nano Ltd is fast-tracking our development programme
Maintaining adherence to medication is often a huge challenge to patients in low- and middle-income countries (LMICs). Reasons for poor adherence can be quite complex. They may run out of tablets and are unable to get a new supply, they may forget to take their medicine or they simply don’t like taking tablets daily due to the difficult side effects they can cause. Regardless of the reason for poor adherence, there is overwhelming evidence that supports the need for a different approach to healthcare within affected communities.
Posted on: 5 April 2023
Stopping TB in its tracks with long-acting injectables: A war of attrition
World TB Day 2023, themed 'Yes! We can end TB!', is set to inspire a renewed sense of hope in the fight against the TB epidemic. The campaign seeks to encourage leaders to take bold steps, increase funding, adopt innovative solutions, and act faster to curb the spread of the disease.
Posted on: 23 March 2023
Community engagement – shaping the long-acting technologies pipeline
The latest World Health Organisation (WHO) reports estimate 58 million people globally have chronic hepatitis C virus (HCV) infection, with about 1.5 million new infections occurring per year. 75% of these cases occur in low- and middle-income countries.\n\nIt is estimated that oral drugs at the point of diagnosis provide a 98% cure rate if an entire oral regimen is completed. However, in LMICs, access to medication can be complex with issues around stigma and pill burden resulting in poor completion rates.
Posted on: 28 July 2022
Developing a single-injection cure for hepatitis C virus for low- and middle-income countries
Dr. David Lee Thomas is a professor of medicine at the Johns Hopkins University School of Medicine. He is trained in internal medicine and infectious diseases and cares for patients with chronic viral hepatitis. Dave leads the Hepatitis C programme for the Unitaid funded LONGEVITY project for CELT.\n\nFrom 2006-2022, Dr. Thomas served as the director of the Division of Infectious Diseases and the Stanhope Bayne-Jones Professor of Medicine. He remains a Professor of Medicine in the School of Medicine and of Epidemiology in the Bloomberg School of Public Health. He is a co-director of the Centre for AIDS Research Clinical Core.\n\nFor world Hepatitis Day 2022, Dr Thomas shared his expertise on hepatitis C virus as a world-leading clinical researcher.
Posted on: 28 July 2022
Saving lives through long-acting injectable innovation
Professor Steve Rannard is Co-director of the Centre of Excellence for Long-acting Therapeutics. Steve leads a team of chemists in developing long-acting formulations for malaria prevention. For World Malaria Day, Steve and his group spent some time to explain how their innovative technology can revolutionise malaria prevention in low- and middle-income countries.
Posted on: 24 April 2022
Reducing the burden of TB in the world’s most in need communities with long-acting injectables
Ketho Angami is a member of the Global TB Community Advisory Board and Long-Acting Technologies Community Advisory Board. In 2016 he received the National Leadership AIDS Award in India, and also the Nagaland State Governor’s award in 2021. Ketho has been engaged in the field of community led advocacy for more than 15 years, working actively in the field of tuberculosis, HIV and viral hepatitis by holding governments accountable for preventable deaths from infectious diseases. He has been engaged with the grassroots population and generating community demands for quality of service on a human rights-based approach.
Posted on: 24 March 2022
Investing in TB prevention strategies with Long-Acting injectables
Susan Swindells is Professor of Internal Medicine in the Section of Infectious Diseases at the University of Nebraska Medical Center, USA. She is a contributing investigator on TB clinical development for the LONGEVITY project. A native of England, Dr. Swindells earned her medical degree from University College London in 1977, with postgraduate training in England and at the University of Washington in Seattle. A clinician and active researcher, Dr. Swindells has many years’ experience in HIV-related translational and clinical research, with a special interest in tuberculosis co-infection.
Posted on: 24 March 2022
Living with TB: My Experience
Monica was raised in a small town called Kohima in North East India. In 2015 she was diagnosed with TB for which she was treated for more than two years. Monica experienced a difficult treatment regimen which included daily injections for nine months and oral medication throughout the duration of her illness. Monica experienced many problems when living with TB including stigma and many difficult side-effects.
Posted on: 24 March 2022
Blog
Dynamic partnerships for maximum impact: How our collaboration with Tandem Nano Ltd is fast-tracking our development programme
Maintaining adherence to medication is often a huge challenge to patients in low- and middle-income countries (LMICs). Reasons for poor adherence can be quite complex. They may run out of tablets and are unable to get a new supply, they may forget to take their medicine or they simply don’t like taking tablets daily due to the difficult side effects they can cause. Regardless of the reason for poor adherence, there is overwhelming evidence that supports the need for a different approach to healthcare within affected communities.
Posted on: 5 April 2023
